NYSE:CNMD

CONMED - CNMD Stock Forecast, Price & News

$89.03

-1.25 (-1.38%)

(As of 12/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $88.56
▼
$91.10
50-Day Range: N/A
52-Week Range: $71.09
▼
$155.51

Volume: 598,104 shs
Average Volume: 373,999 shs
Market Capitalization: $2.71 billion

P/E Ratio: N/A
Dividend Yield: 0.89%
Price Target: $106.00

CONMED MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 19.1% Upside
$106.00 Price Target
Short Interest: Bearish
11.22% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -0.74
Upright™ Environmental Score
News Sentiment: 0.12
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 5.96%
From $3.19 to $3.38 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

834th out of 1,033 stocks

Electromedical Equipment Industry

18th out of 23 stocks

2.5

Analyst's Opinion

Consensus Rating
CONMED has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $106.00, CONMED has a forecasted upside of 19.1% from its current price of $89.03.
Amount of Analyst Coverage
CONMED has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.22% of the outstanding shares of CONMED have been sold short.
Short Interest Ratio / Days to Cover
CONMED has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in CONMED has recently increased by 3.64%, indicating that investor sentiment is decreasing.

0.8

Dividend Strength

Dividend Yield
CONMED has a dividend yield of 0.89%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
CONMED does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, CONMED will have a dividend payout ratio of 23.67% next year. This indicates that CONMED will be able to sustain or increase its dividend.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CONMED has received a 64.86% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Surgical instruments", "Medical technology engineering", and "Training for medical professionals" products. See details.
Environmental Sustainability
The Environmental Impact score for CONMED is -0.74.

2.3

News and Social Media Coverage

News Sentiment
CONMED has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for CONMED this week, compared to 4 articles on an average week.
Search Interest
2 people have searched for CNMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CONMED insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.90% of the stock of CONMED is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CONMED are expected to grow by 5.96% in the coming year, from $3.19 to $3.38 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CONMED is -30.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CONMED is -30.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
CONMED has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
CONMED has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CONMED (NYSE:CNMD) Stock

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

CNMD Stock News Headlines

December 5, 2022 | finance.yahoo.com

CONMED Corporation Announces Quarterly Cash Dividend

December 4, 2022 | americanbankingnews.com

Comparing Masimo (NASDAQ:MASI) & CONMED (NYSE:CNMD)

December 3, 2022 | americanbankingnews.com

CONMED (NYSE:CNMD) and Fc Global Realty (OTCMKTS:FCRE) Head-To-Head Comparison

December 3, 2022 | americanbankingnews.com

Analyzing CONMED (NYSE:CNMD) and Medtronic (NYSE:MDT)

December 2, 2022 | americanbankingnews.com

CONMED (CNMD) & Its Rivals Head-To-Head Contrast

December 2, 2022 | americanbankingnews.com

Critical Survey: CONMED (CNMD) versus The Competition

December 1, 2022 | americanbankingnews.com

Contrasting CONMED (CNMD) & The Competition

December 1, 2022 | americanbankingnews.com

Head to Head Review: CONMED (CNMD) & Its Competitors

November 30, 2022 | americanbankingnews.com

CONMED (CNMD) and Its Peers Financial Contrast

November 30, 2022 | finance.yahoo.com

CONMED Corporation (NYSE:CNMD) Shares Could Be 27% Below Their Intrinsic Value Estimate

November 29, 2022 | americanbankingnews.com

Analyzing CONMED (CNMD) and The Competition

November 29, 2022 | americanbankingnews.com

Critical Analysis: CONMED (CNMD) & Its Peers

November 28, 2022 | americanbankingnews.com

Financial Survey: CONMED (CNMD) & Its Peers

November 25, 2022 | finance.yahoo.com

Why Is Conmed (CNMD) Up 6.8% Since Last Earnings Report?

November 22, 2022 | finance.yahoo.com

CONMED Corporation to Participate in a Fireside Chat at the 34th Annual Piper Sander Healthcare Conference

November 15, 2022 | finance.yahoo.com

CONMED Withdraws FY22 Guidance Due To Disruptions Associated With Software Implementation

November 15, 2022 | markets.businessinsider.com

CONMED Corp. Withdraws Full-year Guidance

November 15, 2022 | finance.yahoo.com

CONMED Corporation Withdraws 2022 Financial Outlook due to Temporary Impact from Software Implementation; Provides 2023 Financial Outlook

November 14, 2022 | reuters.com

CNMD.K - Conmed Corp | Stock Price & Latest News | Reuters

November 13, 2022 | finance.yahoo.com

Analysts Estimate Conmed (CNMD) to Report a Decline in Earnings: What to Look Out for

November 7, 2022 | finance.yahoo.com

CONMED Corporation to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

November 2, 2022 | finance.yahoo.com

CONMED (CNMD) Down on In-Line Q3 Earnings & Lower 2022 View

November 2, 2022 | finance.yahoo.com

Investing in CONMED (NYSE:CNMD) five years ago would have delivered you a 62% gain

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

CNMD Company Calendar

Last Earnings: 10/26/2022
Today: 12/05/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 1/25/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:CNMD
CUSIP: N/A
CIK: 816956
Web: www.conmed.com
Phone: (727) 392-6464
Fax: 315-797-0321
Employees: 3,800
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $106.00
High Stock Price Forecast: $106.00
Low Stock Price Forecast: $106.00
Forecasted Upside/Downside: +19.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 27.91
P/E Growth: 2.74
Net Income: $62.54 million
Net Margins: -7.74%
Pretax Margin: -2.87%
Return on Equity: 14.00%
Return on Assets: 5.24%

Debt

Debt-to-Equity Ratio: 1.45
Current Ratio: 2.75
Quick Ratio: 1.29

Sales & Book Value

Annual Sales: $1.01 billion
Price / Sales: 2.69
Cash Flow: $6.20 per share
Price / Cash Flow: 14.35
Book Value: $26.85 per share
Price / Book: 3.32

Miscellaneous

Outstanding Shares: 30,482,000
Free Float: 28,988,000
Market Cap: $2.71 billion
Optionable: Optionable
Beta: 1.41

Key Executives

Mr. Curt R. Hartman (Age 58)
Chairman, CEO & Pres
Comp: $2M

Mr. Todd W. Garner (Age 53)
Exec. VP & CFO
Comp: $908.45k

Mr. Daniel S. Jonas Esq. (Age 58)
Exec. VP of Legal Affairs, Gen. Counsel & Sec.
Comp: $646.48k

Mr. Patrick J. Beyer (Age 56)
Pres of International & Global Orthopedics
Comp: $1.24M

Mr. Stanley W. Peters III (Age 47)
Pres of Advanced Surgical & Advanced Endoscopic Technologies
Comp: $681.04k

Mr. Peter K. Shagory (Age 53)
Exec. VP of Strategy & Corp. Devel.

Ms. Heather L. Cohen (Age 49)
Exec. VP of HR

Mr. John E. Kennedy (Age 64)
Special Advisor

Ms. Shanna L. Cotti-Osmanski (Age 45)
Exec. VP of Information Technology & CIO

Mr. David R. Murray (Age 74)
Pres of ConMed Electrosurgery

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CNMD Stock - Frequently Asked Questions

Should I buy or sell CONMED stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNMD shares.
View CNMD analyst ratings or view top-rated stocks.
What is CONMED's stock price forecast for 2023?: 1 brokers have issued 12 month price targets for CONMED's shares. Their CNMD share price forecasts range from $106.00 to $106.00. On average, they predict the company's stock price to reach $106.00 in the next year. This suggests a possible upside of 18.3% from the stock's current price.
View analysts price targets for CNMD or view top-rated stocks among Wall Street analysts.
How have CNMD shares performed in 2022?: CONMED's stock was trading at $79.06 at the start of the year. Since then, CNMD stock has increased by 13.4% and is now trading at $89.64.
View the best growth stocks for 2022 here.
Are investors shorting CONMED?: CONMED saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,300,000 shares, an increase of 5.1% from the October 15th total of 3,140,000 shares. Based on an average daily trading volume, of 364,400 shares, the short-interest ratio is currently 9.1 days.
View CONMED's Short Interest.
When is CONMED's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our CNMD earnings forecast.
How were CONMED's earnings last quarter?: CONMED Co. (NYSE:CNMD) posted its quarterly earnings data on Wednesday, October, 26th. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.75 by $0.02. The business had revenue of $275.09 million for the quarter, compared to analysts' expectations of $282.23 million. CONMED had a positive trailing twelve-month return on equity of 14.00% and a negative net margin of 7.74%.

Is CONMED a good dividend stock?: CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.89%.
What guidance has CONMED issued on next quarter's earnings?: CONMED updated its FY 2023 earnings guidance on Tuesday, November, 15th. The company provided earnings per share guidance of $3.20-$3.50 for the period, compared to the consensus EPS estimate of $3.39. The company issued revenue guidance of $1.17 billion-$1.23 billion, compared to the consensus revenue estimate of $1.21 billion.
What is CONMED's stock symbol?: CONMED trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNMD."
Who are CONMED's major shareholders?: CONMED's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.77%), Vanguard Group Inc. (10.95%), State Street Corp (3.53%), Macquarie Group Ltd. (2.41%), Dimensional Fund Advisors LP (2.10%) and AXA S.A. (1.96%).
How do I buy shares of CONMED?: Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CONMED's stock price today?: One share of CNMD stock can currently be purchased for approximately $89.64.
How much money does CONMED make?: CONMED (NYSE:CNMD) has a market capitalization of $2.73 billion and generates $1.01 billion in revenue each year. The company earns $62.54 million in net income (profit) each year or ($2.95) on an earnings per share basis.
How many employees does CONMED have?: The company employs 3,800 workers across the globe.
How can I contact CONMED?: CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The official website for the company is www.conmed.com. The company can be reached via phone at (727) 392-6464 or via fax at 315-797-0321.

This page (NYSE:CNMD) was last updated on 12/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial